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Background-—Cystathionine is an intermediate product in the transsulfuration pathway and formed during the B6-dependent
conversion of methionine to cysteine. Elevated plasma cystathionine has been related to atherosclerosis, which is a major
etiological factor for ischemic stroke. However, the role of cystathionine in stroke development is unknown. Therefore, we
prospectively assessed the association of circulating levels of cystathionine with risk of total and ischemic stroke.
Methods and Results-—Two-thousand thirty-six patients (64% men; median age, 62 years) undergoing coronary angiography for
suspected stable angina pectoris were included. Stroke cases were identified by linkage to the CVDNOR (Cardiovascular Disease
in Norway) project. Hazard ratios with confidence intervals (95% confidence interval) were estimated by using Cox-regression
analyses. During 7.3 years of median follow-up, 124 (6.1%) incident strokes were ascertained, which comprised 100 cases of
ischemic stroke. There was a positive association of plasma cystathionine with risk of total stroke and ischemic stroke.
Comparing the fourth versus the first cystathionine quartiles, age- and sex-adjusted hazard ratios (95% confidence interval) were
2.11 (1.19–3.75) and 2.56 (1.31–4.99) for total and ischemic stroke, respectively. Additional adjustment for major stroke risk
factors only slightly attenuated the associations, which tended to be stronger in patients without previous or existing atrial
fibrillation at baseline (hazard ratio [95% confidence interval], 2.43 [1.27–4.65] and 2.88 [1.39–5.98] for total and ischemic
stroke, respectively).
Conclusions-—In patients with suspected stable angina pectoris, plasma cystathionine was independently related to increased risk
of total stroke and, in particular, ischemic stroke.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00354081. ( J Am Heart Assoc. 2018;7:
e008824. DOI: 10.1161/JAHA.118.008824.)
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S troke is a leading cause of mortality and long-termdisability in the world and remains a massive public
health burden.1 This highlights a pressing need to identify
novel risk associations for stroke and improve our current
understanding of its underlying pathophysiology.
Cystathionine is a sulphur-containing amino acid produced
from homocysteine (Hcy) during the conversion of methionine
(Met) to cysteine (Cys) by the pyridoxal 50-phosphate–
dependent enzymes, cystathionine b-synthase and cys-
tathionine c-lyase.2 In rats, high dietary intake of Met has
been shown to induce hypercholesterolemia,3 in addition to
impairing endothelial morphology and promoting arterio-
sclerosis.4 Increased flux through cystathionine b-synthase
has also been suggested to worsen outcome of ischemic
stroke in experimental studies.5 Notably, elevated circulating
cystathionine concentrations were observed in patients with
cardiovascular disease (CVD),6 and increased levels
were associated with oxidative damage7 and endothelial
dysfunction.4,8 Both these processes play a critical role in the
pathogenesis of atherosclerotic disease9 and hence to clinical
manifestations such as ischemic stroke.1,10 Moreover,
increased expression of cystathionine metabolizing enzymes
have recently been found in human atherosclerotic lesions
and are shown to exacerbate angiogenesis, thereby increasing
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the risk of plaque instability,11 often associated with
atherothrombotic events.12 However, the role of plasma
cystathionine in relation to stroke risk has not previously been
reported.
We conducted a prospective study among patients with
suspected stable angina pectoris to examine the association
of circulating levels of cystathionine with subsequent risk of
total and ischemic stroke.
Methods
Data, analytical methods, and study materials will not be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure.
Study Cohort
A detailed description of the study population has been
published previously.13 In brief, 4164 patients who underwent
coronary angiography for suspected stable angina pectoris at
Haukeland and Stavanger University Hospitals in Western
Norway during 2000–2004 were included. Of these, 2573
(61.8%) were subsequently enrolled in the WENBIT (Western
Norway B-vitamin Intervention Trial; NCT00354081) and
received either (1) folic acid, vitamin B12 and vitamin B6
(n=642), (2) folic acid and vitamin B12 (n=642), (3) vitamin B6
(n=643), or (4) placebo (n=646).14 Because B-vitamin supple-
mentation has been reported to lower the risk of stroke in
some studies,15,16 we excluded patients who received
supplementation with B-vitamins in the WENBIT. In addition,
patients with missing baseline data on cystathionine and 1
patient with an extremely high cystathionine level (20 lmol/L)
were excluded, leaving 2036 patients eligible for the current
analyses (Figure 1).
The study was carried out according to the principles of the
Declaration of Helsinki and was approved by the regional
ethics committee (approval number 2010/1880) and the
Norwegian Data Protection Authority. All study patients
signed a consent form.
Baseline Data
Information on patients’ lifestyle and medical history were
obtained through a self-administered questionnaire and was
validated against hospital records, as previously reported.14
Obesity was identified as having body mass index ≥30 kg/m2.
Current smokers were defined as those who reported
currently smoking, those who quit smoking within <1 month
preceding examination, or having serum cotinine levels
≥85 nmol/L at baseline.13 Diabetes mellitus included types
1 and 2 and was classified according to previous diagnosis or
by having plasma fasting glucose >7 mmol/L, nonfasting
glucose >11.1 mmol/L, or a single measurement of glycated
hemoglobin >6.5%.17 Hypertension was defined according to
existing diagnosis. Left ventricular ejection fraction was
obtained either by echocardiography or ventriculography
during cardiac catheterization. Angiographic extent of coro-
nary artery disease (CAD) was graded as 0 to 3 according to
the number of significantly stenotic coronary arteries.
Follow-up and Study End Points
Patients were followed from angiography until the onset of stroke
or through December 31, 2009 (end of follow-up). The primary
end point was total stroke, including hospitalization or death
attributed to stroke according to the International Statistical
Evaluation of Disease, Tenth Revision (ICD-10; I60–I64 except
I63.6), whereas the secondary endpointwas ischemic stroke (I63
except I63.6). Information on clinical outcomes was obtained
from the CVDNOR (Cardiovascular Disease in Norway) project
(https://cvdnor.b.uib.no/), recording all CVD discharge diagno-
sis from the patient administrative systems at Norwegian public
hospitals during 1994–2009.18 Fatal stroke events were ascer-
tained by record linkage to the Cause of Death Registry at
Statistics Norway (http://www.ssb.no/en).
Biochemical Analyses
Details on the collection of blood samples and biochemical
analyses for relevant clinical indices have been described
previously.13 Among patients recruited at Haukeland University
Hospital, blood samples were drawn 1 to 3 days before
coronary angiography and immediately stored at 80°C,
whereas such samples from patients at Stavanger University
Hospital were drawn after the angiographic procedure and
subsequently transported within 48 hours to the core labora-
tory, until separated and frozen at 80°C. All study-specific
analyses were carried out at the laboratory of Bevital AS (Bergen,
Clinical Perspective
What Is New?
• Higher plasma cystathionine levels are associated with
increased risk of total stroke and ischemic stroke in
patients with suspected stable angina pectoris.
• Risk associations tended to be stronger in patients without
previous atrial fibrillation at baseline.
What Are the Clinical Implications?
• The findings of our study are hypothesis generating and
should be confirmed by additional prospective studies with
alternative designs.
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Norway; www.bevital.no) by laboratory staff blinded to the clinical
outcomes of the patients. Plasma cystathionine, Met, Hcy, and
Cys concentration were determined with gas chromatography/
tandem mass spectrometry.19 Plasma cystathionine had within-
day coefficient of variation of ≤1.8% and between-day coefficient
of variation of ≤3.6%. Serum apolipoprotein A1, apolipoprotein B,
and C-reactive protein (CRP) were measured as previously
described.13 Low-density lipoprotein cholesterol and estimated
glomerular filtration rate (eGFR) were calculated using the
Friedewald and Chronic Kidney Disease Epidemiology Collabora-
tion formula, respectively.
Statistical Analysis
Baseline continuous variables are reported as median (in-
terquartile range), whereas categorical variables are presented
as counts (percentages). Differences in baseline characteris-
tics across plasma cystathionine quartiles were tested with
logistic regression for categorical variables and linear median
regression for continuous and ordinal data. Associations
between cystathionine and related 1-carbon metabolites were
evaluated by Pearson’s correlation, adjusted for age and sex.
Kaplan–Meier curves for stroke events were constructed to
evaluate survival across plasma cystathionine quartiles and
difference tested by the log-rank test. Hazard ratios (HRs) and
95% confidence intervals (CIs) for incident stroke were
estimated using Cox regression models and reported according
to quartiles of plasma cystathionine, with the lowest quartile as
the reference category and per 1-SD increment in-log-
transformed plasma cystathionine. Additionally, HR and 95%
CI for trends across increasing quartiles were assessed to
determine whether their associations with stroke followed a
linear pattern. These trend tests were performed by including
the quartile-specific median cystathionine value as a continu-
ous variable in the Cox proportional hazards model and
assessing significance with the Wald test. The numeric value of
HR greater than 1 was considered a trend toward increased risk
(positive trend) across the lowest to highest quartile of plasma
cystathionine. Proportionality assumptions were assessed by
inspecting log minus log plots and calculating Schoenfeld
residuals. Potential nonlinear relationships between cys-
tathionine and risk of incident strokes were visualized by
generalized additive regression plots for multivariate models.
Patients who did not experience any stroke event during follow-
Figure 1. Flow diagram showing patient selection eligible for the study. WENBIT indicates Western
Norway B-Vitamin Intervention Trial.
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Table 1. Baseline Characteristics According to Quartiles of Plasma Cystathionine
Quartiles of Plasma Cystathionine
Q1 Q2 Q3 Q4 Ptrend* Ptrend
†
Age, y 58 (14) 61 (15) 64 (16) 67 (14) <0.001 
Male sex, n (%) 303 (59.5) 321 (63.1) 322 (63.3) 356 (69.9) 0.001 
Coronary risk factor, n (%)
Obesity 77 (15.2) 100 (19.7) 107 (21.0) 119 (23.4) 0.001 <0.001
Hypertension 189 (37.1) 230 (45.2) 253 (49.7) 276 (54.2) <0.001 <0.001
Diabetes mellitus 211 (41.9) 210 (41.7) 222 (43.6) 267 (52.5) 0.002 0.003
Current smoking 191 (37.6) 160 (31.9) 150 (29.6) 134 (26.5) <0.001 0.16
eGFR, mL/min/1.73 m2 95 (16) 90 (20) 87 (23) 78 (29) <0.001 <0.001
Serum CRP, mg/L 1.58 (2.50) 1.80 (3.0) 1.89 (2.97) 2.12 (3.44) <0.001 <0.001
Plasma ADMA, lmol/L 0.53 (0.15) 0.54 (0.13) 0.58 (0.16) 0.59 (0.17) <0.001 <0.001
Plasma 1-carbon metabolites, lmol/L
Met 25.6 (7.2) 27.4 (8.1) 29.9 (11.3) 31.4 (12.7) <0.001 <0.001
tHcy 9.27 (3.13) 10.5 (3.69) 10.9 (4.27) 12.4 (5.32) <0.001 <0.001
Cys 283 (45.2) 294 (49.2) 298 (50.1) 306 (53) <0.001 <0.001
Plasma B-vitamin status
Folate, nmol/L 11.9 (9.8) 9.81 (7.27) 9.75 (6.51) 9.89 (7.01) <0.001 <0.001
Cobalamin (B12), pmol/L 390 (213) 393 (193) 391 (210) 391 (231) 0.75 0.44
PLP, nmol/L 45.6 (43.6) 42.3 (32.4) 41.9 (31.2) 40.2 (31.9) <0.001 <0.001
Serum lipids
Triglycerides, mmol/L 1.28 (0.86) 1.45 (1.02) 1.52 (1.18) 1.60 (1.11) <0.001 <0.001
ApoB, g/L 0.91 (0. 31) 0.89 (0.35) 0.87 (0.30) 0.86 (0.31) 0.002 0.02
Apo A1, g/L 1.36 (0. 39) 1.34 (0.36) 1.35 (0.36) 1.28 (0.31) <0.001 <0.001
LDL-C 3.1 (1.38) 3.0 (1.45) 2.9 (1.40) 2.8 (1.28) <0.001 <0.001
Previous CVD, n (%)
AMI 166 (32.6) 166 (32.6) 189 (37.1) 228 (44.8) <0.001 0.02
PAD 38 (7.5) 38 (7.5) 49 (9.6) 64 (12.6) 0.002 0.17
AF 35 (6.9) 42 (8.3) 48 (9.4) 60 (11.8) 0.005 0.34
Cerebrovascular disease‡ 26 (5.1) 35 (6.9) 33 (6.5) 54 (10.6) 0.002 0.18
Extent of CAD, n (%) <0.001 0.09
No significant stenosis 225 (44.2) 210 (41.3) 192 (37.7) 141 (27.7)
1-vessel disease 102 (20.0) 83 (16.3) 97 (19.1) 94 (18.5)
2-vessel disease 84 (16.5) 102 (20.0) 99 (19.4) 92 (18.1)
3-vessel disease 98 (19.3) 114 (22.4) 121 (23.8) 182 (35.8)
LVEF (%) 70 (10) 70 (10) 66 (10) 65 (11) <0.001 <0.001
Medications before angiography, n (%)
Aspirin 393 (77.2) 405 (79.6) 395 (77.6) 386 (75.8) 0.46 0.25
Warfarin 18 (3.5) 24 (4.7) 25 (4.9) 47 (9.2) <0.001 0.01
Statins 318 (62.5) 339 (66.6) 348 (68.4) 363 (71.3) 0.002 0.06
b-blocker 333 (65.4) 354 (69.5) 376 (73.9) 388 (76.2) <0.001 0.002
ACEIs 74 (14.5) 84 (16.5) 102 (20.0) 146 (28.7) <0.001 <0.001
Continued
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up were censored. Model 1 included age (years) and sex, and
the multivariate model 2 additionally included the categorical
variables, obesity, diabetes mellitus, hypertension, smoking,
previous acute myocardial infarction, and atrial fibrillation.
Because B-vitamins are crucial in the metabolism of cys-
tathionine20,21 and systemic B-vitamin levels have been
associated with CVD risk,22,23 we did not include these
variables in the main multivariate model. However, to assess
their potential influence on any cystathionine-stroke relation-
ship, these variables were additionally included in an extended
model, as was eGFR, because elevated circulating cystathion-
ine concentrations have been reported in renal patients.21
To investigate effect modifications, survival analyses were
explored according to the median values of continuous
variable and subgroups of categorical variables, and possible
interactions tested by including the interaction products term
in Cox model 2. Moreover, the possibility of unmeasured
confounding was investigated by performing additional sen-
sitivity analysis and applying E-value formula to the multivari-
ate model, according to the recent recommendations for
observational studies.24
Given the hypothesis-testing nature of our analyses, we did
not adjust for multiple comparisons and a P<0.05 was
considered statistically significant.25 Statistical analyses were
performed using SPSS (Sample Power, Version 23; SPSS IBM,
Armonk, NY) and R software (version 3.1.2; The R Foundation
for Statistical Computing, Vienna, Austria).
Results
Baseline Characteristics
Baseline characteristics according to plasma cystathionine
quartiles are presented in Table 1. The study population
consisted of 64.0% men, and median (interquartile range) age
was 62 (16) years, whereas plasma concentrations of
cystathionine were 0.27 (0.20) lmol/L. Cutoffs for serum
plasma cystathionine in quartiles were <0.20, 0.20 to 0.27,
0.27 to 0.39, and >3.20 lmol/L in the first, second, third,
and fourth quartiles, respectively. SD was 0.48 for plasma
cystathionine and 0.61 for log-transformed plasma cystathio-
nine. Patients in the upper quartiles of plasma cystathionine
more often were older, male, and obese and had hyperten-
sion, diabetes mellitus, and established CVD. Accordingly,
Table 1. Continued
Quartiles of Plasma Cystathionine
Q1 Q2 Q3 Q4 Ptrend* Ptrend
†
Medications after angiography, n (%)
Aspirin 362 (71.1) 382 (75.0) 381 (74.9) 398 (78.2) 0.02 0.81
Warfarin 17 (3.3) 26 (5.1) 23 (4.5) 43 (8.4) 0.001 0.02
Statins 349 (68.6) 371 (72.9) 375 (73.7) 397 (78.0) 0.001 0.22
b-blocker 315 (61.9) 330 (64.8) 352 (69.2) 382 (75.0) <0.001 0.004
ACEIs 78 (15.3) 85 (16.7) 106 (20.8) 144 (28.3) <0.001 <0.001
Continuous variables are presented as medians (interquartile range), and categorical variables are reported as counts (%). ACEIs indicates angiotensin-converting-enzyme inhibitors; ADMA,
asymmetric dimethylarginine; AF, atrial fibrillation; AMI, acute myocardial infarction; apoA1, apolipoprotein A1; apoB, apolipoprotein B; BMI, body mass index; CAD, coronary artery disease;
CRP, C-reactive protein; CVD, cardiovascular disease; Cys, cysteine; eGFR, estimated glomerular filtration rate; LDL-C, low-density lipoprotein cholesterol; LVEF, left ventricular ejection
fraction; Met, methionine; PAD, peripheral artery disease; PLP, pyridoxal 50-phosphate; tHcy, total homocysteine.
*Unadjusted.
†Adjusted for age and sex.
‡Composite of stroke, transient ischemic attack, or carotid stenosis.
Figure 2. Stroke-event–free survival. Kaplan–Meier plot show-
ing crude stroke-free survival according to the quartiles of plasma
cystathionine (designated as quartiles 1, 2, 3, and 4). Difference
between quartiles was compared by the log-rank test.
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plasma cystathionine showed an inverse association with left
ventricular ejection fraction and a strong positive relationship
with more-extensive CAD at angiography, also reflected by
more-frequent use of CVD medications among subjects in the
upper cystathionine quartile. Furthermore, we observed
positive associations of cystathionine with serum CRP and
plasma asymmetric dimethylarginine, whereas there were
inverse associations with eGFR.
As anticipated, plasma cystathionine was positively asso-
ciated with the 1-carbon metabolites, plasma Met, total Hcy,
and total Cyst (r=0.24, 0.11, and 0.12, respectively; P<0.001)
and negatively to serum folate and plasma pyridoxal
50-phosphate, whereas no relationship was observed with
serum cobalamin. Patients in the higher cystathionine quar-
tiles also had higher levels of serum triglycerides and lower
serum apolipoprotein A1, apolipoprotein B, and low-density
lipoprotein cholesterol.
Plasma Cystathionine and Risk of Stroke
During a median (interquartile range) follow-up of 7.3 (2.4)
years, an incident stroke event occurred in 124 patients (6.1%),
which comprised 100 (4.9%) cases of ischemic stroke. As
illustrated in Figure 2, there was higher incidences of stroke
throughout higher plasma cystathionine quartiles (P<0.001 for
log-rank test).
Accordingly, we found an approximately linear positive trend
between plasma cystathionine and subsequent risk of stroke
(Figure 3). In an unadjusted model, those in the highest plasma
cystathionine quartile compared with the lowest had increased
risk of total stroke (HR, 3.12; 95% CI, 1.78–5.44). This
association was particularly strong for ischemic strokes (HR,
3.69; 95% CI, 1.92–7.08). Corresponding HRs (95% CIs) were
2.11 (1.19–3.75) and 2.56 (1.31–4.99) in age- and sex-
adjusted analyses and essentially similar in the multivariate
models (Table 2).
Adjusting for previous CVD, extent of CAD, CRP, low-
density lipoprotein cholesterol, or medications at baseline had
no significant effect on the risk associations between plasma
cystathionine and either end point (data not shown).
Met, Hcy, and Cys are important metabolites of 1-carbon
cycle and are closely associated with cystathionine metabo-
lism.2,7 Hence, we also studied the potential influence by
adjusting for these parameters on the cystathionine-stroke
risk associations. In the multivariate model, neither plasma
Met nor Cys were significantly associated with stroke risk,
whereas plasma total Hcy was only borderline positively
related to the risk before controlling for cystathionine
Table 2. Risk Association Between Plasma Cystathionine and Stroke
Plasma Cystathionine
Unadjusted Age and Sex Adjusted Multivariate*
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Total Stroke
Events 124
Q1 Reference Reference Reference
Q2 1.53 (0.82–2.87) 0.18 1.33 (0.70–2.49) 0.37 1.30 (0.69–2.45) 0.42
Q3 2.47 (1.39–4.38) 0.002 1.87 (1.04–3.33) 0.04 1.78 (0.99–3.19) 0.06
Q4 3.12 (1.78–5.44) <0.001 2.11 (1.19–3.75) 0.01 2.01 (1.14–3.61) 0.02
Trend 1.46 (1.23–1.72) <0.001 1.28 (1.08–1.52) 0.004 1.26 (1.06–1.50) 0.01
Per 1-SD† 1.41 (1.22–1.63) <0.001 1.26 (1.07–1.47) 0.005 1.23 (1.05–1.44) 0.01
Ischemic Stroke
Events 100
Q1 Reference Reference Reference
Q2 1.82 (0.88–3.75) 0.11 1.57 (0.76–3.25) 0.22 1.53 (0.74–3.16) 0.26
Q3 2.98 (1.52–5.82) 0.001 2.28 (1.16–4.48) 0.02 2.16 (1.09–4.26) 0.03
Q4 3.69 (1.92–7.08) <0.001 2.56 (1.31–4.99) 0.01 2.39 (1.23–4.72) 0.01
Trend 1.51 (1.25–1.82) <0.001 1.34 (1.11–1.62) 0.003 1.32 (1.09–1.59) 0.005
Per 1-SD† 1.46 (1.25–1.71) <0.001 1.31 (1.11–1.56) 0.002 1.29 (1.09–1.54) 0.004
CI indicates confidence interval; HR, hazard ratio; Q1, first quartile; Q4, fourth quartile.
*Adjusted for age, sex, obesity, diabetes mellitus, hypertension, smoking, previous acute myocardial infarction, and atrial fibrillation.
†Log-transformed.
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(Table 3). However, additional adjustment for these 1-carbon
metabolites or plasma markers of B-vitamins status in the
multivariate model did not appreciably alter the associations
(Table 4), whereas including eGFR slightly attenuated the risk
estimates (HR [95% CI] were 1.88 [1.04–3.41] for total stroke
and 2.19 [1.09–4.41] for ischemic stroke, when comparing
cystathionine quartiles 4–1).
Subgroup Analyses
Figure 4 and Table 5 depict the risk associations between
plasma cystathionine and stroke according to several tradi-
tional risk factors and plasma B-vitamin status, respectively.
Notably, we observed a stronger risk estimate of plasma
cystathionine among patients without than those with previ-
ous atrial fibrillation at baseline (Pinteraction=0.03). The risk
Table 3. Hazard Ratios for Incident Stroke According to Plasma Levels of Methionine, Homocysteine, and Cysteine
Total Stroke Ischemic Stroke
Q4 vs Q1 P Value Per 1-SD* P Value Q4 vs Q1 P Value Per 1-SD* P Value
Plasma Met
Unadjusted 0.92 (0.54–1.57) 0.77 0.88 (0.74–1.06) 0.19 0.93 (0.51–1.67) 0.81 0.89 (0.73–1.09) 0.89
Model 1† 1.04 (0.61–1.78) 0.88 0.92 (0.76–1.09) 0.35 1.05 (0.58–1.89) 0.88 0.93 (0.76–1.13) 0.44
Model 2‡ 1.02 (0.60–1.75) 0.93 0.91 (0.76–1.08) 0.29 1.01 (0.55–1.83) 0.98 0.91 (0.75–1.11) 0.37
Model 3§ 0.91 (0.51–1.62) 0.75 0.87 (0.73–1.06) 0.18 0.90 (0.48–1.75) 0.79 0.88 (0.71–1.08) 0.23
Plasma tHcy
Unadjusted 2.63 (1.55–4.44) <0.001 1.40 (1.21–1.61) <0.001 2.74 (1.55–4.83) <0.001 1.44 (1.23–1.69) <0.001
Model 1† 1.76 (1.01–3.04) 0.05 1.27 (1.08–1.50) 0.003 1.87 (1.03–3.38) 0.04 1.32 (1.11–1.59) 0.002
Model 2‡ 1.49 (0.85–2.60) 0.16 1.21 (1.02–1.45) 0.04 1.57 (0.86–2.87) 0.14 1.24 (1.03–1.54) 0.03
Model 3§ 1.27 (0.72–2.28) 0.39 1.14 (0.95–1.39) 0.12 1.30 (0.71–2.43) 0.40 1.16 (0.97–1.44) 0.10
Plasma tCys
Unadjusted 3.38 (1.91–5.97) <0.001 1.49 (1.26–1.76) <0.001 2.88 (1.51–5.47) <0.001 1.37 (1.14–1.65) 0.001
Model 1† 1.80 (0.99–3.29) 0.54 1.16 (0.96–1.41) 0.10 1.51 (0.77–2.97) 0.23 1.06 (0.87–1.31) 0.56
Model 2‡ 1.75 (0.95–3.21) 0.07 1.13 (0.93–1.36) 0.20 1.44 (0.7–2.85) 0.29 1.02 (0.83–1.26) 0.84
Model 3§ 1.63 (0.89–3.01) 0.12 1.10 (0.91–1.33) 0.31 1.31 (0.66–2.61) 0.44 0.98 (0.81–1.22) 0.96
Met indicates methionine; Q1, first quartile; Q4, fourth quartile; tCyst, total cysteine; tHcy, total homocysteine.
*Log-transformed.
†Adjusted for age and sex.
‡Adjusted for variables in model 1 plus obesity, diabetes mellitus, hypertension, smoking, previous myocardial infarction, and atrial fibrillation.
§Adjusted for variables in model 2 plus plasma cystathionine.
Table 4. Risk Association Between Plasma Cystathionine and Incident Stroke, When Separately Adjusted for Related 1-Carbon
Metabolites and Markers of B-Vitamin Status
Total Stroke Ischemic Stroke
Q4 vs Q1 P Value Per 1-SD* P Value Q4 vs Q1 P Value Per 1-SD* P Value
Plasma cystathionine
Model 2+Met† 2.10 (1.16–3.85) 0.01 1.23 (1.05–1.45) 0.01 2.50 (1.26–5.08) 0.01 1.30 (1.09–1.55) 0.004
Model 2+tHcy† 1.92 (1.05–3.57) 0.04 1.20 (1.03–1.43) 0.04 2.26 (1.10–4.63) 0.03 1.24 (1.03–1.50) 0.03
Model 2+tCys† 1.96 (1.08–3.49) 0.03 1.22 (1.04–1.42) 0.03 2.34 (1.18–4.62) 0.01 1.28 (1.07–1.53) 0.01
Model 2+folate† 2.09 (1.17–3.76) 0.01 1.24 (1.05–1.45) 0.01 2.42 (1.23–4.81) 0.01 1.29 (1.09–1.54) 0.004
Model 2+PLP† 1.95 (1.06–3.59) 0.03 1.21 (1.03–1.44) 0.03 2.27 (1.13–4.64) 0.02 1.26 (1.06–1.53) 0.01
Model 2+Cob† 2.05 (1.04–4.06) 0.04 1.26 (1.05–1.52) 0.02 2.52 (1.12–5.66) 0.02 1.33 (1.09–1.64) 0.01
Cob indicates cobalamin (B12); Met, methionine; PLP, pyridoxal 50-phosphate; Q1, first quartile; Q4, fourth quartile; tCyst, total cysteine; tHcy, total homocysteine.
*Log-transformed.
†Adjusted for age, sex, obesity, diabetes mellitus, hypertension, smoking, previous myocardial infarction, and atrial fibrillation.
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relationship did not differ significantly according to other
subgroup parameters.
Sensitivity Analysis
To elucidate the influence of previous atrial fibrillation further,
we performed additional sensitivity analysis after excluding
patients with previous atrial fibrillation (Figure 1). Notably, we
obtained numerically stronger associations of cystathionine
with risk in the remaining 1851 patients without atrial
fibrillation. In the multivariate model, HR (95% CI) were 2.43
(1.27–4.65; P<0.005) for total stroke and 2.88 (1.39–5.98;
P<0.004) for ischemic stroke, when comparing cystathionine
quartiles 4 to 1.
In addition, application of E-value formula to the multivari-
ate model, also including eGFR, revealed high sensitivity of
the observed association between cystathionine and total
stroke, with an E-value of 3.19 and 1.28 each, for the
estimate and lower reported CI, respectively. Corresponding




In a large cohort of patients undergoing elective coronary
angiography for stable angina pectoris, elevated concentra-
tions of plasma cystathionine were strongly associated with
increased risk of total stroke and ischemic stroke during
follow-up. The risk relationship was independent of several
established stroke risk factor and potential confounders, and
tended to be stronger in patients without previous atrial
fibrillation.
Strengths and Limitations
The major strengths of this study include the large sample
size, detailed clinical information on patient characteristics,
and its prospective design. Although the influence of residual
confounding cannot be ruled out in an observational study,
the risk estimates were consistent also after the adjustment
for major stroke risk factors. Notably, the high E-value
validates the strength and robustness of the observed
findings to the presence of an unmeasured cofounder.24
There are several additional aspects of the present study
that merit consideration. First, because of lack of data, we
were unable to perform separate analyses on the subtypes of
stroke. Second, the current study is based on the measure-
ment of blood parameters at only 1 time point, thus
preventing assessment of the possible variation of cystathion-
ine during follow-up. However, the within-subject reproducibil-
ity has been shown to be fair to good for plasma
cystathionine,26 which allows 1-exposure assessment of
plasma cystathionine status, with reduced risk of regression
dilution bias. Third, we performed multiple subgroup compar-
isons, and it is possible that the significant interaction
between cystathionine and previous atrial fibrillation on stroke
occurrence is attributed to chance (type I error). This is,
however, not immediately supported by our observation of
stronger risk estimates after excluding patients with atrial
fibrillation at baseline. Fourth, the accuracy of self-reported
information on use of medications, disease conditions, and
other health issues pose a concern, despite validation of the
Figure 3. Association of log-transformed plasma cystathionine
with stroke and ischemic stroke. Multivariable models include
age, sex, obesity, diabetes mellitus (yes/no), hypertension (yes/
no), smoking (yes/no), previous acute myocardial infarction (yes/
no), and atrial fibrillation (yes/no). Kernel density plots are
superimposed along the x-axis, to display distribution of plasma
cystathionine. Vertical lines depict the 25th, 50th, and 75th
percentile of the population.
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questionnaires. Fifth, blood samples from Stavanger Univer-
sity hospital were transported to Bevital AS, thus exposing the
samples to room temperature for 3 days. This is unlikely to
have introduced a bias, however, given that plasma cys-
tathionine concentrations are reported to be fairly stable
during short-term storage under such conditions.27 Further-
more, the potential of analytical bias was reduced by using 1
central laboratory for analyzing the plasma samples. Sixth, the
long follow-up time and prospective design minimizes the
potential risk of reverse causation. Yet, we cannot exclude
that patients with established CVD at baseline may also have
had lifestyle modifications or other interventions performed,
which could somehow influence plasma cystathionine status.
Seventh, information on incident stroke end points were
ascertained from the patient administrative database only,
which indicates that cases with asymptomatic stroke without
hospitalization might not have been reported. However, we do
not suspect that such misclassification differs according to
levels of plasma cystathionine. Furthermore, the possibility of
detection bias is unlikely, because each patient’s unique
national identification number was linked to health registries
with almost 100% coverage of all endpoints. Eighth, we
studied patients treated with various medications for CVD,
and thus our results may not be applicable to the general
healthy population. Finally, our results are hypothesis gener-
ating and should be confirmed by additional prospective
studies with alternative designs.
Cystathionine and CVD in Other Epidemiological
Studies
Data on the relationship between cystathionine status and
CVD are scant. In a small study among 14 healthy
participants, plasma cystathionine was related to impaired
vascular function following Met loading.8 Another study
reported high plasma cystathionine levels among patients
with CVD compared with those without CVD.6 To the best of
our knowledge, this is the first large-scale investigation to
demonstrate a significant relationship between plasma cys-
tathionine and subsequent risk of both total stroke and
Figure 4. Forest plot depicting hazard ratios between plasma cystathionine and total stroke according to
several traditional risk factors. Box areas illustrate sample sizes, and horizontal lines depict 95% confidence
intervals (CIs). eGFR indicates estimated glomerular filtration rate; HR, hazard ratio. *Adjusted for age, sex,
obesity, diabetes mellitus, hypertension, smoking, previous myocardial infarction, and atrial fibrillation.
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ischemic stroke. However, the magnitude of risk association
was stronger for ischemic, as compared with total stroke, and
particularly stronger in patients without a history of atrial
fibrillation, suggesting that elevated cystathionine is associ-
ated with the atherosclerotic processes leading to stroke
events.
Possible Mechanisms
Plasma cystathionine, lipids, and CAD
Elevation of plasma cystathionine has been related to an
unfavorable lipid profile.6 Dyslipidemia is a less-well-known
risk factor for stroke28; however, it is pivotal in atheroscle-
rosis and thereby may be linked to stroke.9 Interestingly,
although higher plasma cystathionine was related to an
overall adverse CVD risk profile, including extent of CAD and
previous CVD, we somewhat unexpectedly observed an
inverse association between plasma cystathionine and low-
density lipoprotein cholesterol. However, this may be
attributed to statin therapy, which was received by a majority
of the patients. Nevertheless, adjusting for these parameters
did not attenuate the risk estimates, implying that factors
other than those traditionally predisposing to atherosclerosis
are likely to play a role in the relationship between
cystathionine and stroke development.
Plasma cystathionine and inflammation
Previous studies have reported increased cystathionine
concentrations in patients with asthma, a condition known
to be related to systemic inflammation.29 Accordingly, in our
study, plasma cystathionine concentration was directly asso-
ciated with CRP, a marker of inflammation.30 Accumulating
data indicate that inflammation may play a key role in the
pathophysiology of atherothrombosis.30 However, adjusting
for CRP did not influence the relationship between cystathion-
ine and stroke risk, indicating that the associations are not
mediated solely by CRP-related inflammation.
Plasma cystathionine, endothelial dysfunction, and
oxidative stress
Both experimental and clinical data have shown that
increased systemic cystathionine levels are related to alter-
ations in endothelial function.4,8 Endothelial dysfunction,
characterized by reduced nitric oxide–mediated vasodilatation
of arteries, is a crucial step in the early formation of
atherosclerotic lesions9 and is associated with plaque
progression and subsequent ischemic stroke events.10 It is
therefore interesting that plasma cystathionine demonstrated
a positive association with asymmetric dimethylarginine in our
study, given that asymmetric dimethylarginine may induce
vascular dysfunction through suppression of endothelial nitric
oxide synthase.31 In addition, systemic cystathionine eleva-
tion has previously been related to impaired downstream
catabolism to cysteine, rather than increased production per
se.7,32 Reduced cystathionine-transsulfuration may impair
glutathione production and thereby lead to oxidative stress.7
Oxidative stress can, in turn, further impair endothelial
morphology by inactivating nitric oxide,9 in addition to
mediating several other biological processes such as lipid
peroxidation and induction of vascular lesions.1 Notably, a
previous study from a subsample of the current cohort
showed that higher plasma cystathionine concentration are
related to low levels of reduced glutathione,33 indicating
impaired antioxidant defence.7
Plasma status of cystathionine
Elevated cystathionine may simply be a marker of high Met
intake, which enhances flux through cystathionine b-
synthase.2,4 This could explain a strong association between
plasma cystathionine and Cys at baseline. However, a
prospective study in 26 556 male Finnish smokers found no
significant association between Met intake and risk of
stroke.34 Accordingly, we observed no significant relationship
between either plasma Met or Cys with stroke risk, making
them unlikely as confounders. Likewise, cystathionine
remained a significant predictor of stroke risk even after the
adjustment for Hcy. Although we cannot exclude the influence
of this metabolic precursor on our results, it is, however,
unlikely that the observed associations of cystathionine with
stroke in the current study are confounded by Hcy status.
Alternatively, high plasma cystathionine may reflect subopti-
mal nutritional status.20,21 In this regard, previous studies
showed that low serum concentrations of B-vitamins, in
particular vitamin B6, were strongly associated with high
Table 5. Association Between Plasma Cystathionine Per SD
(Log-Transformed) and Total Stroke According to Plasma
Markers of B-Vitamin Status
Subgroups Events/Total HR (95% CI)* P Value Pint
Folate
<Median 55/1015 1.20 (0.92–1.55) 0.027 0.56
≥Median 69/1015 1.21 (0.96–1.51) 0.09
PLP
<Median 80/1011 1.26 (1.03–1.55) 0.02 0.58
≥Median 44/1014 1.13 (0.85–1.49) 0.40
Cob
<Median 46/800 1.39 (1.05–1.84) 0.02 0.44
≥Median 41/800 1.15 (0.86–1.51) 0.34
CI indicates confidence interval; Cob, cobalamin (B12); HR, hazard ratio; PLP, pyridoxal
50-phosphate.
*Adjusted for age, sex, obesity, diabetes mellitus, hypertension, smoking, previous
myocardial infarction, and atrial fibrillation.
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cystathionine levels.21,29 However, any influence by poor
nutrition status seems unlikely, because plasma levels of
B-vitamins neither attenuated the association between
plasma cystathionine and stroke events nor introduced any
significant effect modification. Conceivably, renal mechanism
may be considered given that elevated circulating cystathion-
ine has been observed in patients with renal disease, possibly
attributed to the combination of reduced urinary excretion
and increased production.21 This could explain our observa-
tion of negative correlation of cystathionine with eGFR.
Notably, renal dysfunction is a major risk factor for ischemic
stroke.35 However, including eGFR had a minor influence on
our estimates, suggesting other mechanisms than renal
impairment being responsible for the current findings.
Conclusions
In conclusion, our observational study suggests that elevated
plasma cystathionine is associated with increased risk of total
stroke and ischemic stroke in patients with stable angina
pectoris, particularly in those without a history of atrial
fibrillation. Our results motivate future studies to elucidate the
role of cystathionine in stroke development.
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